| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|---|---|---|---|---|---|
Operating activities | ||||||
Net loss | ||||||
-76,970 | -86,420 | -120,875 | -58,068 | -85,779 | -59,504 | -14,943 |
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||||||
Depreciation | ||||||
11,100 | 6,600 | 6,100 | 6,040 | 5,679 | 4,470 | 5,084 |
Amortization of finance lease right-of-use assets | ||||||
10,307 | 0 | 0 | - | - | - | - |
Net accretion of discount on investments | ||||||
3,667 | 42 | -1,844 | -2,729 | 2,997 | 658 | 841 |
Unrealized loss (gain) on cash equivalents and short-term equity investments | ||||||
88 | -1,120 | -2 | 0 | 0 | - | - |
Gain on disposal of property and equipment | ||||||
42 | -53 | -3 | 0 | -98 | 10 | 1 |
Stock-based compensation | ||||||
66,267 | 52,142 | 37,539 | 32,132 | 27,681 | 18,698 | 3,444 |
Realized foreign currency gain | ||||||
0 | 1,074 | 0 | 0 | - | - | - |
Tax benefit on unrealized gain on available-for-sale securities | ||||||
- | - | - | -211 | 0 | 0 | - |
Realized loss on sales of available-for-sale securities | ||||||
0 | 87 | 143 | 37 | 203 | 0 | 301 |
Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | ||||||
-35,229 | 55,232 | -1,996 | -4,957 | 1,952 | -4,041 | 8,711 |
Inventories | ||||||
6,887 | 0 | 0 | - | - | - | - |
Prepaid expenses and other current assets | ||||||
128,598 | 129 | 1,911 | -1,099 | -978 | 1,628 | -791 |
Other assets | ||||||
3,253 | -1,090 | 2,365 | 136 | 420 | 795 | 547 |
Accounts payable | ||||||
-3,051 | 3,630 | -714 | -298 | 1,970 | 3,485 | -2,041 |
Accrued and other liabilities | ||||||
18,288 | 5,606 | 9,196 | 2,965 | -2,126 | 18,878 | 11,307 |
Deferred revenue | ||||||
-49,941 | -5,031 | 174 | 13,225 | 27,654 | 33,557 | 30,885 |
Lease obligations | ||||||
0 | 32 | 1,023 | 814 | 627 | 814 | 690 |
Accrued interest for finance lease liabilities | ||||||
194 | 0 | 0 | - | - | - | - |
Other long-term liabilities | ||||||
52,360 | 1,636 | 1,619 | 1,897 | 4,225 | -250 | -580 |
Net cash provided by (used in) operating activities | ||||||
-78,705 | -76,144 | -66,513 | 7,108 | -18,571 | 22,414 | 25,918 |
Purchases of property and equipment | ||||||
5,762 | 8,020 | 8,500 | 1,252 | 1,977 | 8,118 | 6,806 |
Proceeds from sale of property and equipment | ||||||
7 | 184 | 5 | 0 | 2 | 10 | 2 |
Purchases of available-for-sale securities and term deposit | ||||||
411,299 | 576,880 | 169 | 9,041 | 41,736 | 144,727 | 0 |
Proceeds from sales of available-for-sale securities | ||||||
0 | 8,167 | 21,109 | 4,298 | 15,342 | 0 | 16,582 |
Proceeds from maturities of investments | ||||||
537,072 | 54,426 | 57,421 | 12,617 | 22,501 | 45,546 | 1,000 |
Net cash provided by (used in) investing activities | ||||||
120,018 | -522,123 | 69,866 | 6,622 | -5,868 | -107,289 | 10,778 |
Financing activities | ||||||
Borrowings under capital lease obligations | ||||||
0 | 49 | 0 | 0 | - | - | - |
Borrowings under credit facility | ||||||
- | - | - | - | - | - | 11,500 |
Repayments under credit facility | ||||||
- | - | - | - | - | - | 11,500 |
Repayments of capital lease obligations | ||||||
0 | 6 | 0 | 0 | 403 | 403 | 329 |
Repayments of finance lease liabilities | ||||||
11,925 | 0 | 0 | - | - | - | - |
Repayments of lease obligations | ||||||
403 | 403 | 403 | 403 | - | - | 403 |
Proceeds from follow-on offerings, net of underwriting discounts and commission costs | ||||||
0 | 0 | 471,205 | 0 | 0 | - | - |
Proceeds from lease financing liability | ||||||
- | - | - | - | - | - | 553 |
Proceeds from convertible promissory note | ||||||
- | - | - | - | - | - | 600 |
Proceeds from non-controlling interest | ||||||
- | - | - | - | - | - | 175 |
Proceeds from initial public offering, net of underwriting discounts and commission costs | ||||||
- | - | - | - | - | 155,933 | 0 |
Proceeds from AstraZeneca private placement | ||||||
- | - | - | - | - | 20,000 | 0 |
Cash paid for payroll taxes on restricted stock unit releases | ||||||
12,750 | 15,612 | 8,296 | 2,740 | 2,243 | 0 | - |
Proceeds from issuance of common stock | ||||||
20,778 | 29,847 | 34,910 | 9,881 | 14,992 | 1,697 | 84 |
Payments of deferred offering costs | ||||||
0 | 0 | 944 | 0 | 0 | 3,135 | 0 |
Net cash used in financing activities | ||||||
-4,300 | 13,875 | 496,472 | 6,738 | 12,346 | 174,092 | 680 |
Effect of exchange rate change on cash and cash equivalents | ||||||
-5 | -8 | 51 | -10 | -38 | -94 | 84 |
Net decrease in cash and cash equivalents | ||||||
37,008 | -584,400 | 499,876 | 20,458 | -12,131 | 89,123 | 37,460 |
Supplemental cash flow information: | ||||||
Interest payments | ||||||
174 | 218 | 255 | 295 | 335 | 377 | 433 |
Balance in accounts payable and accrued liabilities related to purchases of property and equipment | ||||||
460 | 276 | 3,781 | 356 | 931 | 280 | 1,655 |
Assets acquired under facility lease | ||||||
- | - | - | - | - | - | 3,067 |
Deferred offering costs recorded in accounts payable and accrued liabilities | ||||||
0 | 24 | 35 | 0 | 0 | 974 | 0 |